Introduction by Myers, SL
Introduction 
T.E. Starzl 
I T has been little more than 3 years since Ochiai et all presented a preliminary report of FK 506 at the meet-
ing of the International Transplantation Society in Hel-
sinki. FK 506 had been developed by Kino. Sawada. Ooto. 
and other workers at the Fa.tiisawa Company. but the first 
reports of this work did not appear in the literature until 
1987.2.3 A few weeks after the Helsinki meeting, Dr Satoru 
Todo and I flew to Japan. where arrangements were made 
with company officials for a smaU supply of FK 506 to be 
tested in Pittsburgh. PA. In vitro systems of evaluation 
were used at first and, subsequently, experiments were 
carried out in rats, dogs, and subhuman primates. 
Progress with this drug came fast and, in June 1987, at 
the European Society of Organ Transplantation meeting in 
Oothenberg, a satellite symposium on FK 506 was held.3 
The proceedings, which were published as a monograph, 
had the appropriate title "FK 506: A Potential Break-
through in Immunosuppression." The promise was there, 
but the toxicity profiles that were presented from the 
University of Pittsburgh investigators were not reconcil-
able with those developed in Cambridge.) The drug ap-
peared to the English investigators to be intolerably toxic. 
However, it had been impossible at that juncture to do 
kinetic or good dose control studies of the drug, since there 
was not a satisfactory assay system. This deficit was 
remedied by the announcement at the Gothenberg meeting 
by Tamura et al" of a sensitive assay method which made 
subsequent research far more discriminating. 
Today, we return to the European Society of Organ 
Transplantation, where much new information will be 
given about FK 506, with particular emphasis on the 
clinical trials in Pittsburgh, PA, which began in February 
1989. The most extensive experience has been with liver 
/063 
transplant recipients, and this experience can be divided 
into two components. The first was from the "rescue" 
treatment of patients whose liver grafts were failing be-
cause of rejection despite state-of-the-art treatment with 
conventional immunosuppression. The second, and later, 
component was in patients who were treated from the 
outset with FK 506. In our original plans, it was hoped to 
use FK 506 with eyA because these two agents had been 
shown to be synergistic in animals. However, the FK 506 
was found to greatly aggravate CyA toxicity and, conse-
quently, FK 506 was used alone.5 
What has been learned about FK 506 is now extremely 
extensive. You may judge for yourself the extent to which, 
in the time ahead, the clinical use ohhis drug will permit or 
contribute to the next plane of achievement in transplan-
tation. 
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